felzartamab   Click here for help

GtoPdb Ligand ID: 13455

Synonyms: Jingfei® (China) | MOR-03087 | MOR-202 | MOR03087 | MOR202
Approved drug Immunopharmacology Ligand
felzartamab is an approved drug
Compound class: Antibody
Comment: Felzartamab (MOR03087; MOR202) is a humanized anti-CD38 monoclonal antibody. It has immunosuppressive action and induces Fc-effector function. Anti-CD38 monoclonals are intended to target long-lived CD38+ autoantibody-secreting plasma cells and plasmablasts that persist in inflamed tissue and bone marrow niches, to mediate immunosuppression.
Click here for help
No information available.
Summary of Clinical Use Click here for help
Felzartamab (MOR03087) was progressed as a clinical candidate for the treament of relapsed/refractory multiple myeloma (MM), renal autoimmune diseases, and for the management of antibody-mediated renal allograft rejection. FDA Breakthrough Therapy Designation was granted (late 2023) for the treatment of primary membranous nephropathy. First approval was issued by China's NMPA in August 2026, to treat MM in combination with lenalidomide and dexamethasone.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01421186 A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma Phase 1/Phase 2 Interventional MorphoSys AG
NCT05021484 Felzartamab in Late Antibody-Mediated Rejection Phase 2 Interventional Medical University of Vienna 3-4
NCT04893096 MOR202 for Refractory MN Phase 2 Interventional Mario Negri Institute for Pharmacological Research 1,3-4